Navigation Links
Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
Date:10/25/2010

EAST BRUNSWICK, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its previously announced process to identify, following the approval of KRYSTEXXA™ by the U.S. Food and Drug Administration (FDA), a strategic transaction for the sale of the Company did not result in a sale of the Company at this time. The board of directors will continue to evaluate strategic alternatives available to the Company to maximize value.

The Company is working toward the commercial launch of KRYSTEXXA, which it expects will be available by prescription in the U.S. later this year.  The Company will host a conference call on Tuesday, October 26, 2010, at 8:30 a.m. during which it will provide further detail around its launch plans.

Conference Call Information

Savient's management team will host a live conference call and webcast on October 26, 2010 at 8:30 a.m. Eastern Time. Call-in information will be provided in a separate press release shortly.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase), which was approved by the FDA on September 14, 2010 for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
2. Savient Pharmaceuticals To Hold First Quarter 2010 Results
3. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
5. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
6. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
7. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
8. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
9. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
10. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
11. Savient Provides Update on Pegloticase BLA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LA JOLLA, Calif. , Sept. 18, 2014 ... RGLS ), a biopharmaceutical company leading the ... announced today it has initiated its ATHENA natural ... syndrome, a life-threatening genetic kidney disease with no ... characterize the natural decline of renal function markers ...
(Date:9/18/2014)... and ROCKVILLE, Md. , ... SPPI ), a biotechnology company with fully integrated ... in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ...
(Date:9/18/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that the Company,s President and ... , will present at the 7 th ... September 24, 2014 at 11:20 a.m. EDT.  ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
(Date:9/18/2014)... 2014 Kent, WA Chiropractor Danene Saggau ... pleased to announce that Dawn Kelly has agreed to become ... Saggau looks forward to Ms. Kelly expanding her role within ... make her a key contributor. “ Dawn Kelly brings ... and personal experiences that will allow me to focus ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Memorial ... made history this week by performing the first ever, ... UNOS (United Network for Organ Sharing) approval to launch ... one of only two programs in South Florida. ... Dr. Enrique Gongora, Medical Director of the ...
(Date:9/18/2014)... 2014 (HealthDay News) -- Exposure to diverse communities may ... Hearing different languages in the park or ... learn from people who are different from them, researchers ... adults, are often biased against interacting with and learning ... Woodward, a University of Chicago psychology professor, said in ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay News) -- ... starting to spread faster than ever, the World Health Organization said ... infection were reported in just one week. That brings the ... of those reported in the past three weeks, the Associated ... WHO has estimated that as many as 20,000 people could eventually ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 It’s been just ... their newest, patent pending bunion splint to website visitors, but ... Rosa, wrote: "I was absolutely delighted. It is perfect and ... I am wearing them. THANK YOU FOR LISTENING!!!" Another ... by saying, "The hole used to slip to the end ...
Breaking Medicine News(10 mins):Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3
... - New $2.1 Million SBIR Grant Extends NHGRI ... Whole Genome Imaging and Analysis Platform -PHILADELPHIA, March ... nanoscale platforms for biomedical research, molecular diagnostics and ... II grant from the National Human Genome Research ...
... During the 14th International Salon of,Ophthalmologic Optics held ... the Second National Optical Award Grand Prix MSOO. , ... of optical products got their first,opportunity to choose the ... together with Expocentre, the largest exhibition,organization of Russia, announced ...
... Way People Think About End-of-LifeReceives Praise from Award-Winning Documentary Filmmaker ... the nation,s leading non-profit hospice organizations, has produced a documentary ... will be televised on Detroit Public Television on Monday, March ... 29 from 4:30 - 5:30 pm. For television ...
... relationship agreement that Legacy Hospital Partners, Inc. (LHP), based in Plano, ... range of supply chain and procurement services to help manage spending ... ... March 17, 2009-- Broadlane announced today through a corporate relationship agreement ...
... study by the Stanley Medical Research Institute and Johns ... to neurotic behavior in infected men and women. Between ... and 30 percent of the U.S. population - may be ... then passed to humans when changing cat litter, gardening and ...
... one of the few area surgeons performing the Reverse Shoulder Replacement ... ... -- A breakthrough shoulder surgery is restoring function and relieving pain ... a damaged rotator cuff, a failed shoulder replacement surgery or severe ...
Cached Medicine News:Health News:BioNanomatrix Awarded Phase II NIH Grant to Support Development of Its Single-Molecule Nanoscale Whole Genome Analyzer 2Health News:Prizes of the Grand Prix MSOO Award Presented in Moscow 2Health News:Hospice of Michigan Documentary to Air on Detroit Public Television Monday, March 23 and Sunday, March 29 2Health News:New Corporate Agreement with Legacy Hospital Partners, Inc. Names Broadlane Exclusive Provider of Supply Chain and Procurement Services 2Health News:New Corporate Agreement with Legacy Hospital Partners, Inc. Names Broadlane Exclusive Provider of Supply Chain and Procurement Services 3Health News:New Corporate Agreement with Legacy Hospital Partners, Inc. Names Broadlane Exclusive Provider of Supply Chain and Procurement Services 4Health News:Research Finds Popular Household Pets Transmit Dangerous Parasites to Humans 2Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 2Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 3Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 4
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests....
Calibration plasmas for Assays of Low Molecular Weight Heparins (LMWH)using the Anti-Xa method on STA© Analyzers....
Multi-constituent Calibration Plasma for Functional Assays of Coagulation Parameters on STA© Analyzers....
Multi-constituent normal and abnormal plasma controls for routine and specialty assays performed on the STA© family of hemostasis analyzers....
Medicine Products: